Patients (n = 90) with NSCLC in non-metastasized but locally advanced stages IIIA and IIIB after standard radio-chemotherapy (60–70 Gy; platinum based chemotherapy) will be enrolled and treated four times every 2–6 weeks with ex vivo TKD/IL-2 stimulated NK cells [139]. The gene discussed is IL2; the disease is non-small cell lung carcinoma.